Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
| Autor: | Weilan Wang, Bingkun Xiao, Dezhi Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Bevacizumab Colorectal cancer ramucirumab antiangiogenic monoclonal antibodies bevacizumab Gastroenterology OncoTargets and Therapy law.invention Ramucirumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine Lung cancer Original Research business.industry medicine.disease bleeding Vascular endothelial growth factor meta-analysis Oncology chemistry 030220 oncology & carcinogenesis Relative risk Pulmonary hemorrhage business medicine.drug |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Bingkun Xiao,1 Weilan Wang,2 Dezhi Zhang3 1Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, China; 2Department of Pharmacy, Chinese PLA General Hospital, Beijing, China; 3Department of Pharmacy, The 264th Hospital of PLA, Taiyuan, Shanxi, China Aim: Bevacizumab and ramucirumab are antiangiogenic monoclonal antibodies, which target vascular endothelial growth factor-A and vascular endothelial growth factor receptor-2, respectively, used in various cancers. Bleeding events have been described with these two agents. We conducted an up-to-date meta-analysis to determine the relative risk (RR) associated with the use of antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab. Methods: This meta-analysis of randomized controlled trials was performed after searching PubMed, American Society for Clinical Oncology Abstracts, European Society for Medical Oncology Abstracts, and the proceedings of major conferences for relevant clinical trials. RR and 95% CIs were calculated by random-effects or fixed-effects models for all-grade and high-grade bleeding events related to the angiogenesis inhibitors.Results: Eighty-five randomized controlled trials were selected for the meta-analysis, covering 46,630 patients. The results showed that antiangiogenic monoclonal antibodies significantly increased the risk of all-grade (RR: 2.38, 95% CI: 2.09–2.71, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|